Bioventus Inc. (BVS)
$13.56+0.22%Close
SELLRECOVERY · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $919M
- Beta
- 0.64
- P/E (TTM)
- 16.88
- Short % float
- 6.77%
- Days to cover
- 6.7
- SI change
- +7.9%
- 1W
- +3.51%
- 1M
- +3.04%
- vs SPY 1W
- +3.65%
- vs SPY 1M
- +0.53%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 63
- VALUE
- 44
- GROWTH
- 60
- GARP
- 61
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC17.0%
REV YoY-
ROE28.4%
EPS YoY-
ROA8.1%
GROSS68
OP11
NET9
[VALUATION]
P/E TTM16.88
P/E FWD16.67
SECTOR PE20.34
INDUSTRY PE22.66
P/B4.03
P/FCF-
EV/EBITDA11.11
EV/EBIT-
PEG1.64
FCF YIELD-
RISK
INT COV-
D/E115.52
ALTMAN Z-
CURR RATIO1.69
ND/EBITDA-
BETA0.64
Company news
FAQ
- What is LOPJLB’s current signal on BVS?
- LOPJLB’s latest quantitative signal on Bioventus Inc. (BVS) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is BVS in?
- Bioventus Inc. (BVS) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Bioventus Inc. (BVS) do?
- Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The companyâs product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthr…